The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

Background The primary manifestation of coronavirus disease 2019 (COVID‐19) is
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …

Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

Objective To perform a scoping review of how patients with COVID-19 are affected by acute
limb ischaemia (ALI) and evaluate the recommendations of the 2020 ESVS ALI Guidelines …

Thromboembolic events are frequent and life-threating complications of COVID-19 but are
also observed in patients with sepsis. Disseminated thrombosis can occur despite …

Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …

Thromboprophylaxis in hospitalized patients with COVID-19 has been associated with a
survival benefit and is strongly recommended. However, the optimal dose of …

Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous
thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial …

Two years since the outbreak of the novel coronavirus SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2) pandemic, there remain few clinically effective drugs to …

Coronavirus disease 2019 (COVID-19), a life-threatening infectious disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is causing the worst …